{
    "title": "107_hr2747",
    "content": "The \"Stem Cell Research for Patient Benefit Act of 2001\" mandates the implementation of National Institutes of Health guidelines for research using human pluripotent stem cells. The Director of NIH is required to conduct or support research using these cells from embryos and fetal tissue in accordance with the guidelines published in the Federal Register. Additionally, a study on stem cells by the National Institutes of Health is also mandated. The Director of the National Institutes of Health will conduct a study on the biological properties of stem cells from embryos, fetal tissues, and adult tissues, their differences, ability to generate tissues, potential clinical uses, emerging applications, and the effectiveness of guidelines within 5 years of enactment. The Director of the National Institutes of Health will submit a report on the findings and conclusions of a study on stem cells to the relevant committees in Congress within 5 years of the Act's enactment. A study will be conducted on therapies for immunological rejection of stem cells and tissue derived from stem cells. The Secretary of Health and Human Services will seek an agreement with the Institute of Medicine to conduct a study on therapies for immunological rejection of stem cells and tissue derived from stem cells, comparing their potential therapeutic value and identifying safeguards against misuse of human embryos created by somatic cell nuclear transfer. The Secretary of Health and Human Services will seek an agreement with an appropriate entity to conduct a study on therapies for diseases. The study must be completed within 2 years, and a report on the findings and conclusions must be submitted to specific committees in the House of Representatives and the Senate. The Biomedical Advisory Commission is established. The Biomedical Advisory Commission, known as the Commission, is tasked with studying bioethical issues and emerging biomedical research to make recommendations for the development of effective therapies while considering ethical, social, legal, and regulatory aspects. The Biomedical Advisory Commission, known as the Commission, is composed of 13 members appointed by various leaders from different sectors including legal, ethical, scientific, medical, patient, religious, and industry communities. The Commission appointments are made in consultation with relevant communities. The Chairperson is elected by majority from Commission members. Each member serves a 3-year term and can be reappointed. Vacancies are filled as per original appointment method. The Commission meets at least 2 but not more than 4 times a year. Members are compensated at a specified rate. The Commission members are compensated at a rate equivalent to level III of the Executive Schedule. Federal employees on the Commission cannot receive additional pay. Travel expenses are provided according to applicable provisions. The Commission members are compensated at a rate equivalent to level III of the Executive Schedule, and travel expenses are provided. The Executive Director, appointed by the Secretary of Health and Human Services, is paid at a rate not to exceed level V of the Executive Schedule. Additional staff can be appointed by the Executive Director as needed. The Commission staff shall be paid according to federal pay regulations. The Executive Director and staff will be appointed following civil service laws. The Commission has the authority to hold hearings, gather information from government agencies as needed. The Commission can request nonconfidential information from US departments or agencies to fulfill its duties. The Administrator of General Services can provide administrative support services upon request. The Commission can enter into contracts and compensate government or private entities for supplies and services. The Commission is authorized to submit reports to Congress. The Commission can submit reports to Congress and the President as requested. The Commission will terminate 6 years after the enactment of this Act."
}